标题
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
作者
关键词
immune checkpoint, companion diagnosis, PD-L1, tumor mutation burden, immune score
出版物
Frontiers of Medicine
Volume 13, Issue 1, Pages 32-44
出版商
Springer Nature
发表日期
2019-01-25
DOI
10.1007/s11684-018-0678-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
- (2018) Martin Reck Immunotherapy
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
- (2016) Woo Young Sun et al. Journal of Translational Medicine
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
- (2016) R. Mandal et al. Cancer Discovery
- Multiplexed tissue biomarker imaging
- (2016) Edward C. Stack et al. Journal for ImmunoTherapy of Cancer
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
- (2015) H. M. Kluger et al. CLINICAL CANCER RESEARCH
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immune Checkpoint Blockade in Malignant Mesothelioma
- (2015) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
- (2015) Zipei Feng et al. Journal for ImmunoTherapy of Cancer
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Deconstructing the Peptide-MHC Specificity of T Cell Recognition
- (2014) Michael E. Birnbaum et al. CELL
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
- (2013) Nancy E. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
- (2012) Jae Hyuk Lee ARCHIVES OF SURGERY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
- Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
- (2011) Caroline Jochems et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- DNA replication fidelity and cancer
- (2010) Bradley D. Preston et al. SEMINARS IN CANCER BIOLOGY
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
- (2009) Hong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started